![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
NBB-001 (boronophenylalanine) is an ionising radiation emitter, which is currently being evaluated for the treatment of recurrent head-and-neck cancer.
Lead Product(s): P-Borono-L-Phenylalanine
Therapeutic Area: Oncology Product Name: NBB-001
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 10, 2024
Details:
BPA (boronophenylalanine) is an engineered targeting boron pharmaceuticals to deliver the cellular precision and curative power of BNCT. It is being evaluated for the treatment of head and neck, brain, breast, melanoma and other cancers.
Lead Product(s): P-Borono-L-Phenylalanine
Therapeutic Area: Oncology Product Name: BAP
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 21, 2023